BR112015021483A2 - arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer - Google Patents

arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer

Info

Publication number
BR112015021483A2
BR112015021483A2 BR112015021483A BR112015021483A BR112015021483A2 BR 112015021483 A2 BR112015021483 A2 BR 112015021483A2 BR 112015021483 A BR112015021483 A BR 112015021483A BR 112015021483 A BR112015021483 A BR 112015021483A BR 112015021483 A2 BR112015021483 A2 BR 112015021483A2
Authority
BR
Brazil
Prior art keywords
adi
peg
antibodies
arginine deiminase
cancer treatment
Prior art date
Application number
BR112015021483A
Other languages
English (en)
Inventor
A Thomson James
Yang Lee
Chen Li-Chang
E Showalter Richard
Almassy Robert
Shia Wei-Jong
Sisson Wes
Original Assignee
Polaris Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group filed Critical Polaris Group
Publication of BR112015021483A2 publication Critical patent/BR112015021483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

resumo patente de invenção: "arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer". a presente invenção refere-se genericamente a proteínas arginina deiminase (adi) isoladas que têm uma reatividade cruzada reduzida com anticorpos anti-adi-peg 20, em comparação com adi-peg 20, mas que podem ter características funcionais comparáveis ou melhores do que as de adi-peg 20, as composições que compreendem as proteínas da adi, e os métodos relacionados de tratamento de doenças dependentes de arginina ou de doenças afins, tais como o câncer. 1/1
BR112015021483A 2013-03-15 2014-03-13 arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer BR112015021483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790833P 2013-03-15 2013-03-15
PCT/US2014/026766 WO2014151982A2 (en) 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
BR112015021483A2 true BR112015021483A2 (pt) 2017-10-10

Family

ID=51581665

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021483A BR112015021483A2 (pt) 2013-03-15 2014-03-13 arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer

Country Status (13)

Country Link
US (2) US11235037B2 (pt)
EP (2) EP3744341A1 (pt)
JP (1) JP6382934B2 (pt)
KR (2) KR102455753B1 (pt)
CN (1) CN105188739B (pt)
AU (1) AU2014236653B2 (pt)
BR (1) BR112015021483A2 (pt)
CA (1) CA2901795C (pt)
ES (1) ES2805360T3 (pt)
HK (2) HK1214139A1 (pt)
RU (1) RU2015141932A (pt)
SG (1) SG11201507354QA (pt)
WO (1) WO2014151982A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828656T3 (es) 2012-04-04 2021-05-27 Polaris Group Composición que comprende arginina desiminasa pegilada
JP6382934B2 (ja) 2013-03-15 2018-08-29 ポラリス グループ 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
SG11201607736UA (en) 2014-03-18 2016-10-28 Tdw Group Engineered chimeric pegylated adi and methods of use
WO2016007625A1 (en) 2014-07-08 2016-01-14 Tdw Group Antibodies to argininosuccinate synthase and related methods
US9789170B2 (en) * 2014-09-16 2017-10-17 Polaris Group Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
TWI699210B (zh) * 2015-03-18 2020-07-21 開曼群島商瑞華藥業集團 工程化之嵌合聚乙二醇化ａｄｉ及使用方法
WO2018085551A2 (en) * 2016-11-02 2018-05-11 Polaris Group Formulations of pegylated arginine deiminase
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
CN108324951B (zh) * 2018-04-16 2021-05-25 薛剑峰 一种精氨酸脱亚胺酶注射剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
EP1337630A2 (en) 2000-11-28 2003-08-27 Phoenix Pharmacologics, Inc. Modified arginine deiminase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
US20070212311A1 (en) 2003-10-07 2007-09-13 University Of Florida Research Foundation, Inc. Recombinant Alkalinizing Bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
WO2010083312A2 (en) 2009-01-14 2010-07-22 The Trustees Of The University Of Pennsylvania Micro-rna biomarker in cancer
WO2011053871A2 (en) * 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
FR2978416B1 (fr) 2011-07-26 2013-11-29 Decathlon Sa Vehicule, par exemple du type trottinette, avec systeme de repliage
US8663967B2 (en) * 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
ES2828656T3 (es) 2012-04-04 2021-05-27 Polaris Group Composición que comprende arginina desiminasa pegilada
JP6382934B2 (ja) 2013-03-15 2018-08-29 ポラリス グループ 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
SG11201607736UA (en) 2014-03-18 2016-10-28 Tdw Group Engineered chimeric pegylated adi and methods of use
US9789170B2 (en) 2014-09-16 2017-10-17 Polaris Group Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment

Also Published As

Publication number Publication date
KR20210069126A (ko) 2021-06-10
EP3744341A1 (en) 2020-12-02
US20140348814A1 (en) 2014-11-27
EP2968482B1 (en) 2020-05-06
WO2014151982A3 (en) 2015-01-08
SG11201507354QA (en) 2015-10-29
AU2014236653A1 (en) 2015-09-10
HK1214139A1 (zh) 2016-07-22
WO2014151982A2 (en) 2014-09-25
US20220105160A1 (en) 2022-04-07
EP2968482A4 (en) 2016-07-20
JP6382934B2 (ja) 2018-08-29
AU2014236653B2 (en) 2019-04-18
CA2901795C (en) 2022-08-02
RU2015141932A (ru) 2017-04-26
CN105188739A (zh) 2015-12-23
KR20150129728A (ko) 2015-11-20
ES2805360T3 (es) 2021-02-11
KR102263038B1 (ko) 2021-06-14
US11235037B2 (en) 2022-02-01
CN105188739B (zh) 2017-06-23
JP2016519069A (ja) 2016-06-30
CA2901795A1 (en) 2014-09-25
KR102455753B1 (ko) 2022-10-17
HK1219232A1 (zh) 2017-03-31
EP2968482A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112015022462A2 (pt) inibidores de ido
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
BR112015006060A2 (pt) agentes de ligação kir3dl2
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
CR20160229A (es) Inhibidires de bromodominio
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
EA201591762A1 (ru) Человеческие антитела к grem1
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112017002703A2 (pt) anticorpos específicos de mmp9.
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
BR112018009361A2 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: TDW GROUP (TW)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]